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Background: Contemporary recommendations regarding the duration of follow-up after radical pros-
tatectomy (RP) are highly heterogeneous. Protocol-based follow-up schemes have been implemented to
facilitate the expeditious identiﬁcation of patients with recurrence. The aim of this study is to assess the
reliability and comfort of general practitioners (GPs) in follow-up of RP.
Methods: Following institutional ethical approval, we performed a retrospective review in patients
undergoing follow-up after RP between January 2004 and December 2010. Patient factors, disease var-
iables, and follow-up prostate speciﬁc antigen (PSA) compliance was collected. “Noncompliant” follow-
up care was deﬁned as: patients that had not received a PSA for a 14 month period within 5 years of
prostatectomy. Patient and disease-based risk factors for noncompliant follow-up were assessed. GPs
were also surveyed in their follow-up practice of RP patients, to assess their familiarity in caring for these
patients.
Results: In total, 65 cases were identiﬁed that met the inclusion criteria. At 60 months of follow-up, 66%
(43/65) of patients had a compliant follow-up regime. For patients with noncompliant follow-up at
60 months, median time of compliance did not differ signiﬁcantly when assessing preoperative PSA,
Gleason sum, extraprostatic extension, or surgical margin status. Of the GPs surveyed, 68% of GPs felt
comfortable in follow-up of RP patients. Some 62% of GPs would expect the PSA to be < 0.1 and 25% of
GPs would measure the PSA annually.
Conclusion: Our study identiﬁed that follow-up by GPs after RP is insufﬁcient. Accordingly, there is a
requirement for formal educational programs if primary care is to take a greater role in follow-up of
these patients.
Copyright © 2016 Asian Paciﬁc Prostate Society, Published by Elsevier. This is an open access article under
the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Prostate cancer is among the most common malignancy diag-
nosed in men.1 Radical prostatectomy (RP) remains as the standard
of care for organ-conﬁned prostate cancer and provides excellent
oncological outcomes.2,3 Following RP, a proportion of patients
require additional cancer therapy, such as radiation or hormonal
manipulation.4 These additional therapies are typically instigatedellington Hospital, 36 Gurkha
ie).
ciﬁc Prostate Society, Published bupon diagnosis of disease recurrence.5 At present, prostate speciﬁc
antigen (PSA) represents the prominent biomarker for disease
recurrence following prostate cancer treatment.6 Accordingly, the
prompt diagnosis of elevated PSA (and likely disease recurrence) is
essential as it may effect cancer-speciﬁc survival. Prompt diagnosis
implies a lesser risk of disseminated disease and may increase
treatment options available.
Therefore, it is important to have a robust effective means to
follow-up these patients. Contemporary guidelines outlining
postprostatectomy follow-up are highly heterogeneous and con-
ﬂicting. Of these, recommendations range between follow-up pe-
riods from 6 months to lifetime. Traditionally, the follow-up hasy Elsevier. This is an open access article under the CC BY-NC-ND license (http://
Table 2
Disease parameters for patients.
Disease parameter n ¼ 65
Median PSA (ng/mL) 7.0
Median Gleason grade 7
Extracapsular extension 26% (n ¼ 17)
þve margin 20% (n ¼ 13)
Biochemical failure 8% (n ¼ 5)
Median time to recurrence 43 mo
PSA, prostate speciﬁc antigen.
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ever, over the past decades, an increasing demand on outpatient
clinics has been observed. Additionally, hospital-based follow-up
represents a signiﬁcant source of health care expenditure. These
factors have led to the development of nurse-led follow-up clinics.
The predominant view of UK health professionals expressed in a
qualitative study in 2011 was that there is scope for primary care to
occupy a greater role.7
To date, there is limited data assessing the reliability and com-
fort of primary health care physicians with follow-up of prosta-
tectomy patients in the community.We aimed to assess compliance
with general practitioner (GP)-based postprostatectomy regimes.
We further aimed to identify patient-related risk factors for poor
follow- up compliance. Finally, we aimed to assess GPs' under-
standing of postprostatectomy follow-up.
2. Materials and methods
Following institutional ethical approval, we identiﬁed patients
that underwent RP between January 2004 and December 2010 by a
single surgeon. Patients were excluded if they failed to reach an
undetectable PSA postoperatively, experienced biochemical recur-
rence within 2 years of RP, died within this 2 year time frame, had
incomplete documentation, did not have a minimum of 5 years
follow-up, or were not discharged to the care of their GP.
The study was performed at Nelson Hospital, Nelson Marl-
borough, New Zealand. This represents a regional center, consisting
of a population of 50,000. Given logistical and accessibility issues,
the typical practice of the involved surgeon included a 2 year
follow-up after RP. Following this, patient care was transferred to
their respective GP for further follow-up. Upon transfer, GPs were
advised to perform annual PSA blood tests and refer back to
specialist care if there was a detectable PSA or any concerns with
complications arising from surgery.
We retrospectively reviewed physical and electronic records.
Data collected included: patient demographics (age, comorbidities,
ethnicity), prostate cancer (preoperative PSA, ﬁnal prostate pa-
thology, extraprostatic extension, surgical margin status), and
follow-up details (postprostatectomy PSA frequency, follow-up
period, presence of biochemical recurrence). To access PSA data,
the local laboratory system was accessed and all preoperative and
postoperative PSA values were recorded. PSA recordings were
categorized in 5 month intervals following prostatectomy.
Biochemical failure after RP was deﬁned as a PSA of 0.2 or
higher, as consistent with the current European Association of
Urology and American Urological Association recommenda-
tions.5,8,9 Noncompliant patient follow-up was deﬁned as patients
who did not have a post RP PSA reading for 14 months. Duration of
compliance was calculated by determining the PSA reading at the
longest follow-up interval. Patients that underwent complete PSA
assessment to 60 months of follow-up were deemed compliant.
This was used as a surrogate marker for reliability of follow-up.
An anonymous electronic online survey (Survey Monkey, Palo
Alto, CA, USA) was sent to all of the 118 GPs regularly practicing inTable 1
Questionnaire submitted to participating general practitioners.
Questionnaire
(1) Do you feel comfortable following up patients following radical prostatectomy for
(2) What PSA would you normally expect following a radical prostatectomy for prosta
(3) How frequently would you check PSA in patients following a radical prostatectom
(4) When would you refer back a patient to urology services following a radical prosta
(5) Would you be prepared to any attend educations sessions regarding PSA testing fo
(6) Any other questions or suggestions?
PSA, prostate speciﬁc antigen.the catchment of the Nelson Hospital health service. This survey
was aimed to assess the comfort of GPs in following up RP patients
and their understanding of how these patients should be followed
up (summarized in Table 1).
Data was entered in an Excel 2013 spreadsheet (Microsoft,
Redmond, CA, USA). Analysis was performed using SPSS v20 (SPSS
Inc., Chicago, IL, USA). Data was deﬁned as categorical or contin-
uous. Categorical data were analyzed using Fishers' exact test or
c2as appropriate. Continuous data were tested for distribution.
Parametric continuous datawere compared using one-way analysis
of variance.3. Results
In total, 65 patients were identiﬁed who met the inclusion
criteria. Patient demographics and disease characteristics are
highlighted in Table 2. During the study period, overall follow-up
compliance was 42% (27/65) following transfer of care to their GP
and 58% (28/65) were “noncompliant”. However, at 60 months of
follow-up, 66% (43/65) of patients had compliant follow-up. During
follow-up, ﬁve patients were identiﬁed as suffering biochemical
recurrence. Of these, two cases were not referred back by the GP to
the hospital. The remaining three patients were referred back to the
urology department and were seen at a median 14 days post-
recurrence. These cases represented local recurrence and were
referred to radiation oncology for consideration of salvage
radiotherapy.
Assessing patient factors as risk for noncompliant follow-up, no
factors resulted as statistically signiﬁcant predictors. Speciﬁcally:
preprostatectomy PSA > 10 [relative risk (RR) ¼ 0.98, 95% conﬁ-
dence interval (CI): 0.43e2.21], Gleason sum of  7 (RR 2.6, 95% CI:
0.41e16.3, P ¼ 0.32), presence of extraprostatic extension
(RR ¼ 0.63, 95% CI: 0.257e1.59, P ¼ 0.32), and positive surgical
margins (RR ¼ 0.65, 95% CI: 0.23e1.89, P ¼ 0.43). For patients with
noncompliant follow-up at 60 months, median time of compliance
did not differ signiﬁcantly when assessing preoperative PSA,
Gleason sum, extraprostatic extension, or surgical margin status.
In total, 118 GPs were sent the survey and of these, 47 responses
were obtained. Amajority of GPs self-reported being comfortable in
following up with patients after RP. Some 73% of GPs correctly
expected a nondetectable or <0.1 PSA value after RP. Conversely,
27% of GPs deﬁned biochemical recurrence at higher levels or were






Summary of results of survey completed by general practitioners (GPs).
Do you feel comfortable following up patients following RP for Prostate Cancer?
N ¼ 46
Comfortable 67% (n ¼ 31)
Not comfortable 33% (n ¼ 15)
What PSA would you normally expect following a RP for Prostate Cancer ? n ¼ 47
Undetectable 13% (n ¼ 6)
< 0.1 60% (n ¼ 28)
< 1 15% (n ¼ 7)
< 4 2% (n ¼ 1)
10 2% (n ¼ 1)
Low 2% (n ¼ 1)
Dependent on time postoperation 2% (n ¼ 1)
Unsure 4% (n ¼ 2)
How frequently would you check PSA in patients following a RP? n ¼ 46
Annually 28% (n ¼ 13)
6e12 monthly 39% (n ¼ 18)
3e6 monthly 15% (n ¼ 7)
Guided by Urologist, clinical guidelines, or discharge summary 11% (n ¼ 5)
Not at all 2% (n ¼ 1)
Unsure 4% (n ¼ 2)
When would you refer back a patient to Urology services following a RP?
PSA rise alone 40% (n ¼ 19)
Complications or symptoms of recurrence alone 6% (n ¼ 3)
PSA rise and/or symptomatic of recurrence/complication 43% (n ¼ 20)
As per discharge letter 2% (n ¼ 1)
Any questions 2% (n ¼ 1)
Unsure 6% (n ¼ 3)
Prostate Int 4 (2016) 136e139138Of the GP respondents, 83% reported interest in attending
educational sessions on follow-up of RP patients. Suggestions from
GPs surveyed were as follows:
- Guidelines for PSAmonitoring post-RP bemade available via the
Regional Pathways website
- PSA results for RP patients were not ﬂagged as being post-
operative on their laboratory results systems, and thus were
viewed and appraised without the appropriate normal range of
values
- Clearer instructions on discharge summaries and clinic letters
for GPs4. Discussion
RP remains as a prevalent treatment option in organ-conﬁned
prostate cancer. Meticulous follow-up is critical to ensure treat-
ment success and detect disease recurrence promptly. Signiﬁcant
health care economic burden has prompted the introduction of
nurse-led and primary care physician-based follow-up regimes
postprostatectomy. Limited literature assessing the suitability of
GP-based follow-up regimes following RP is available. From our
study, we determined that, at present, transfer of follow-up care
results in suboptimal postprostatectomy follow-up regimes.
Postprostatectomy follow-up is complex, with multiple critical
factors to be assessed. Most importantly, patients may be promptly
identiﬁed following disease recurrence. Approximately one third of
patients suffer from recurrence of disease regardless of treatment
modality.10,11 In current practice, the PSA serum marker is a simple
method of detecting disease recurrence after RP. International
guidelines agree on the essential role of routine PSA testing in
prostate cancer follow-up.8,12 Typically, following prostatectomy,
an undetectable PSA level of < 0.2 is expected, in keeping with total
eradication of prostate tissue, and thus cure. During follow-up, a
detectable PSA suggests biochemical recurrence of prostate cancer
and requires prompt assessment, and may require further diseasemanagement. Further, signiﬁcant advances in molecular imaging
have allowed identiﬁcation of biochemical recurrence at very low
PSA levels.13 Early identiﬁcation of disease recurrence prior to
metastatic spread allows for a wider repertoire of treatment op-
tions. A robust reliable follow-up regime is required in order to
identify patients who require further treatment for prostate cancer
recurrence. A recent systematic review highlighted the in-
consistencies between follow-up recommendations regarding
duration and frequency of PSA tests.14 Of these recommendations,
interval between PSA tests in the 1st year following RP varies be-
tween 3 months and 12 months. Currently, the New Zealand Best
Practice Advocacy Centre guidelines and the UK NICE guidelines are
in agreement regarding the recommended frequency of PSA tests
following RP. PSA testing should start at 6 weeks at the earliest,
with 6 monthly testing for the ﬁrst 2 years, and then at least
annually thereafter.7,15e17
In the current economic climate, there has been a considerable
push to reduce the burden of hospital-based services to primary
care facilities. In the setting of prostate cancer, nurse-led clinics
have been used in several centers in New Zealand, suggesting it is a
safe reasonable approach.18 Current literature supports the
involvement of primary health care clinicians in the setting of
oncological follow-up. Our survey illustrated that up to 67% of
primary health care physicians felt “comfortable” in following up
postprostatectomy patients. Of the participating clinicians, over
80% correctly identiﬁed PSA testing frequency as annually or more
frequently following RP. These ﬁndings are in accordance with a
recent systemic review, which suggested that a greater GP role in
cancer care could improve the quality of patient care for cancer
survivors.12,19 Lewis et al19 suggested that hospital follow-up might
prompt unnecessary tests, raise anxiety, provide false reassurance,
and delay the patient's return to full function. This systemic review
found no difference in patient wellbeing, survival, and recurrence
rates between colon and breast cancer patients followed up in
primary care compared with those followed up in secondary care,
although the follow-up period was limited and studies were not
well powered.
Conversely, there is controversy whether primary care based
regimes are able to provide an effective follow-up service.20 The
ﬁndings of the current study highlighted that a signiﬁcant pro-
portion of patients following prostatectomy received insufﬁcient
follow-up when managed by primary health care service-based
follow-up regimes. Clinician-based factors may account for a pro-
portion of these patients with noncompliant follow-up. While
approximately 70% of primary health care physicians surveyed
were aware that following prostatectomy PSA should be unde-
tectable, the remainder incorrectly identiﬁed concerning PSA
levels. It should be noted that over 80% of the participating prac-
titioners were interested in participating in educational training
sessions. These ﬁndings are corroborated by Watson et al7 who
demonstrated that GPs were content to provide a greater role in
prostate cancer patients following RP, however they needed greater
guidance and support.17
In our study, we recommended an annual PSA upon discharge to
primary healthcare physicians.15 Despite this, at 5 years follow-up,
only 66% of patients had compliant follow-up. These ﬁndings are in
accordance with previous literature. Goodall et al21 recently
assessed postprostatectomy follow-up with a strict algorithm-
based regime. This group reported compliance of 74% at 24-
month follow-up. In addition to clinician-based factors, patient-
related factors must be considered when determining causation
for noncompliant follow-up postprostatectomy. Intuitively, pa-
tients with higher risk disease are more likely to be involved and
cooperative with their respective disease management. Despite
this, high risk disease characteristics, including high initial PSA,
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margins, did no infer a reduced risk of noncompliant follow-up. In
these patients, meticulous follow-up is critical to ensure acceptable
oncological outcomes. Accordingly, discharge of high risk patients
for GP follow-up may not be suitable. To date, multiple strategies
have been trialed to improve patient compliance. For example,
mobile health messaging services have been assessed in alternate
domains of medicine.22,23 Current literature highlights signiﬁcant
heterogeneity of outcomes, likely a result of varying methodology.
A recent Cochrane review outlined some beneﬁt in the compliance
of chronic disease.24 Such management may be of beneﬁt in the
current assessed model of postprostatectomy follow-up.
There are several limitations of the current study. Firstly, there
are inherent limitations with studies of a retrospective nature.
Secondly, due to ethical and logistical issues, we were unable to
collate data on patients that moved out of the study district.
Further, the primary physician cohort included in the current study
may not be truly reﬂective of the practice throughout the
remainder of the country. A national study including practices
throughout the country may provide more generalizable informa-
tion. The current study highlights the willingness of primary health
care physicians to be involved in prostate cancer management.
Finally, data pertaining to a GP's understanding of other pertinent
postprostatectomy outcomes were not collected. While this was
not the primary aim of the current study, understanding of the
importance of urinary incontinence and erectile function is critical
in acceptable postprostatectomy follow-up. Formal guidelines in
primary care prostate cancer follow-up are required, particularly in
the evolving ﬁeld of prostate cancer management and improved
prostate cancer biomarkers.6,25
In conclusion, although most primary health care physicians are
comfortable in following up patients following RP, a signiﬁcant
portion of patients are not reliably followed up in this setting.
Further education and collaboration between the hospital and
primary care may help to align management strategies and follow-
up of these patients.
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